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Abstract
Background: The polymorphism of plasminogen activator inhibitor-1 (PAI-1) 4G/5G gene has been indicated to be correlated
with coronary artery disease (CAD) susceptibility, but study results are still debatable.
Objective and Methods: The present meta-analysis was performed to investigate the association between PAI-1 4G/5G
gene polymorphism and CAD in the Chinese Han population. A total of 879 CAD patients and 628 controls from eight
separate studies were involved. The pooled odds ratio (OR) for the distribution of the 4G allele frequency of PAI-1 4G/5G
gene and its corresponding 95% confidence interval (CI) was assessed by the random effect model.
Results: The distribution of the 4 G allele frequency was 0.61 for the CAD group and 0.51 for the control group. The
association between PAI-1 4G/5G gene polymorphism and CAD in the Chinese Han population was significant under an
allelic genetic model (OR=1.70, 95% CI=1.18 to 2.44, P=0.004). The heterogeneity test was also significant (P,0.0001).
Meta-regression was performed to explore the heterogeneity source. Among the confounding factors, the heterogeneity
could be explained by the publication year (P=0.017), study region (P=0.014), control group sample size (P=0.011), total
sample size (P=0.011), and ratio of the case to the control group sample size (RR) (P=0.019). In a stratified analysis by the
total sample size, significantly increased risk was only detected in subgroup 2 under an allelic genetic model (OR=1.93, 95%
CI=1.09 to 3.35, P=0.02).
Conclusions: In the Chinese Han population, PAI-1 4G/5G gene polymorphism was implied to be associated with increased
CAD risk. Carriers of the 4G allele of the PAI-1 4G/5G gene might predispose to CAD.
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Introduction
The plasminogen activator inhibitor-1 (PAI-1), a key regulating
factor, determines endogenous fibrinolysis activity. The elevated
plasma concentration or activity of PAI-1 is one of the relevant
signs of atherosclerosis and thrombus disease [1]. Many studies
have demonstrated that elevated PAI-1 activity is an independent
predictor of coronary artery disease (CAD) and myocardial
infarction (MI) [2]. Local plasmin generation is inhibited by
elevated PAI-1, leading to decreased fibrinolysis activity, throm-
bosis, and fibrin deposition; local plasmin generation likewise
facilitates atherosclerosis progress and vascular occlusion.
The PAI-1 gene, located in 7q21.3–22, spans 12.3 kb and
contains 9 exons and 8 introns. The polymorphism of the 4G/5G
gene is located in the PAI-1 gene promoter region. The 5
th
guanine (G base) is inserted or deleted in the 4 G sequence in the –
675
th base of the transcription initial point upstream. The PAI-1
gene has three genotypes, namely, 4G4G, 4G5G, and 5G5G.
4G4G allele carriers always have higher plasma PAI-1 activity
than 4G5G and 5G5G carriers [3].
In 2006, Ye et al. performed a meta-analysis on seven
hemostatic gene polymorphisms in coronary disease in Caucasians
and African-Americans. They reported that the PAI-1 (–675) 4G
variant yields a per-allele relative risk of 1.06 (1.02 to 1.10) for
coronary disease. However, their study had an indication of
publication bias [4]. In 2009, Isordia-Salas I et al. found that the
4G allele is an independent risk factor for acute MI in young
patients, similar to smoking, hypertension, and a family history of
inherited cardiovascular disease in Mexico [5]. In 2010, Abboud
N et al. found that the MI risk is notably high in 4 G carriers with
elevated plasma PAI-1 in a Tunisian population [6]. However, in
2011, Rallidis LS et al. found that the 4 G allele of PAI-1 4G/5G
polymorphism is less frequent among very young survivors of MI
compared with that in matched controls in Greece [7]. In 2011,
Ashavaid TF et al. found that PAI-1 4G/5G gene polymorphism
does not affect the severity of CAD in an Indian population [8].
Studies on the association between PAI-1 4G/5G gene
polymorphism and CAD have been extensively performed in
China, but the results are still disputable. In 2001, Dai Y et al.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33511reported that PAI-1 4G/5G gene polymorphism is not associated
with susceptibility for CAD [9]. The point was favored by another
study [10]. However, other studies had opposite observations [11–
16]. Therefore, the present meta-analysis, which included 1,507
participants, was performed to draw a valuable conclusion on the
relationship between PAI-1 4G/5G gene polymorphism and CAD
in the Chinese Han population (File S1).
Materials and Methods
Publication Search and Inclusion Criteria
The electronic databases PubMed, Embase, Web of Science,
China Biological Medicine Database, and China National
Knowledge Infrastructure were searched using the MeSH terms
‘‘coronary artery disease’’ or ‘‘coronary heart disease,’’ ‘‘polymor-
phism,’’ ‘‘plasminogen activator inhibitor-1,’’ ‘‘gene,’’ and ‘‘Chinese.’’
The included studies were published from 2001 to 2008 (last
research updated on July 04, 2011).
The selected studies had to be in accordance with the following
major criteria: a) evaluation of PAI-1 4G/5G gene polymorphism
and CAD in a Chinese Han population; b) diagnosis of CAD in
accordance with the examination results of coronary arteriography
(.50% stenosis of at least one major vessel), as well as clinical
symptoms combined with electrocardiogram, echocardiography,
treadmill exercise test, and myocardial perfusion imaging in
emission computed tomography (ECT); c) controls proven to have
no CAD either by coronary arteriography or by medical history,
blood test, physical examination, electrocardiogram, echocardiog-
raphy, treadmill exercise test, and ECT; and d) no other
cardiovascular risk factors such as hypertension, hyperlipidemia,
and diabetes mellitus (applied to all participants, including cases
and controls).
Data Extraction
The data were obtained according to a standard protocol.
Studies that were repeated, did not meet the inclusion criteria, or
provided little data were excluded. If the same data appeared in
different works, the result was only used once. The collected data
comprised the name of the first author, publication year, region,
number of genotypes, genotyping, study design, matching criteria,
and total number of cases and controls.
Statistical Analysis
The association between PAI-1 4G/5G gene polymorphism and
CAD was compared using the odds ratio (OR) corresponding to a
95% confidence interval (CI). The presence of inter-study
heterogeneity was calculated by the Chi-square-based Q-test,
and significance was set at the P,0.05 level [17]. The
inconsistency index I
2 was calculated to assess the variation
caused by the heterogeneity. If heterogeneity was observed among
the studies, the random-effects model was used to estimate the
pooled OR (the DerSimonian and Laird method) [18]. Otherwise,
the fixed-effects model was adopted (the Mantel–Haenszel
method) [19]. The Z test was used to determine the pooled OR
with the significance set at P,0.05.
Fisher’s exact test was used to assess the Hardy–Weinberg
equilibrium (HWE) with the significance set at P,0.05. The
potential publication bias was estimated by the funnel plot. Egger’s
linear regression test on the natural logarithm scale of the OR was
used to assess the funnel plot asymmetry; the significance was set at
Table 1. Characteristics of the investigated studies of the association between PAI-1 4G/5G gene polymorphism and coronary
artery disease.
Author Year Region CAD Control
Sample Size (CAD/
control)
4G4G 4G5G 5G5G 4G4G 4G5G 5G5G
Dai Y[9] 2001 Beijing 85 110 55 35 48 12 250/95
Fu Y [11] 2001 Beijing 58 49 16 38 85 49 123/172
Guan LX [12] 2002 Shandong 50 52 24 23 70 28 126/121
Li XS[10] 2002 Guangdong 13 18 5 5 11 0 36/16
Wang YS[13] 2003 Shandong 8 35 24 2 7 21 67/30
Yin SQ[14] 2003 Tianjin 24 22 9 11 29 8 55/48
Xia DS[15] 2006 Tianjin 79 67 20 18 28 17 166/63
Zhan M [16] 2003 Tianjin 40 14 2 25 52 6 56/83
Abbreviations: PAI-1: plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0033511.t001
Table 2. Summary of meta-analysis of association of PAI-1 4G/5G gene polymorphism and coronary artery disease risk.
Number CAD size Con size Pooled OR (95% CI) P value Pheterogeneity
Chinese Han population 8 879 628 1.70(1.18–2.44) 0.004* ,0.0001*
Subgroup 1(total size.200) 4 665 451 1.56(0.95–2.57) 0.08 0.04*
Subgroup 2(total size,200) 4 214 177 1.93(1.09–3.35) 0.02* ,0.0001*
Abbreviations: CI: confidence interval; OR: odds ratio; number: literature number; CAD size: the total number of CAD cases; Con size: control group size, the total
number of control group;
*P,0.05.
doi:10.1371/journal.pone.0033511.t002
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all statistical analyses (StataCorp, College Station, TX, USA).
Results
Studies and Populations
A total of 22 papers were obtained by the literature search,
among which 8 fit the inclusion criteria. Of the 14 excluded
studies, 3 papers were redundant studies, 5 were reviews, 2
deviated from the HWE, and 4 were not involved with PAI-1 4G/
5G gene polymorphism. The data were collected from 879 CAD
patients and 628 controls (Table 1, File S2) [9–10,11–16]. The five
surveyed regions comprised the provinces of Beijing, Shandong,
Guangdong, Jiangsu, and Tianjin.
Pooled Analyses
The distribution of the 4 G allele frequency was 0.61 for the
CAD group and 0.51 for the control group. The association
between PAI-1 4G/5G gene polymorphism and CAD in the
Chinese Han population was significant under an allelic genetic
model (OR=1. 70, 95% CI=1.18 to 2.44, P=0.004) (Table 2
and Figure 1).
The heterogeneity test was also significant (P,0.0001). Meta-
regression was performed to explore the heterogeneity source.
Among the confounding factors, the heterogeneity could be
explained by the publication year (P=0.017), study region
(P=0.014), control group sample size (P=0.011), total sample
size (P=0.011), and RR (P=0.019). In a stratified analysis by the
total sample size, significantly increased CAD risk was detected in
subgroup 2 under an allelic genetic model (OR=1.93, 95%
CI=1.09 to 3.35, P=0.02). No significant increased CAD risk was
detected in subgroup 1 under an allelic genetic model (OR=1.56,
95% CI=0.95 to 2.57, P=0.08). Studies with a total size of .200
were included in subgroup 1, and the residual studies with a total
size of ,200 were included in subgroup 2 (Tables 2, 3, and 4 and
Figure 2).
Bias Diagnostics
The publication bias of the studies was assessed using the funnel
plot and Egger’s test. Publication bias was not seen in the funnel
plot (Figure 3). No statistically significant difference was found in
the Egger’s test, indicating low publication bias in the current
meta-analysis (T=2.09, P=0.082).
Figure 1. Forest plot of coronary artery disease associated with 4G/5G gene polymorphism (distribution of 4G allelic frequency of
plasminogen activator inhibitor-1 4G/5G gene).
doi:10.1371/journal.pone.0033511.g001
Table 3. The confounding factors for the potential sources of heterogeneity studied by meta-regression.
Study Year Region Case size Con size Tot size RR Weight OR LnOR
Dai Y [9] 2001 1 250 95 345 2.63 14.71 0.78 –0.25
Fu Y [11] 2001 1 123 172 295 0.72 14.73 2.32 0.84
Guan LX [12] 2002 1 126 121 247 1.04 14.54 1.65 0.50
Li XS [10] 2002 2 36 16 52 2.25 8.57 0.82 –0.20
Wang YS [13] 2003 1 67 30 97 2.23 9.91 2.74 1.01
Yin SQ [14] 2003 1 55 48 103 1.15 12.08 1.54 0.43
Xia DS [15] 2006 1 166 63 229 2.63 13.81 3.28 1.19
Zhan M [16] 2003 1 56 83 139 0.67 11.64 2.04 0.71
Abbreviations: Year: publication year; Region 1: northern China; Region 2: southern China; Case size: CAD group sample size; Con size: the total number of control
group; Tot size: total sample size; RR: the ratio of case size to control size; LnOR: the natural logarithm of odds ratio for the 4G allelic distribution frequency of PAI-1 gene
4G/5G polymorphism between CAD and control groups.
doi:10.1371/journal.pone.0033511.t003
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The current meta-analysis included 879 CAD patients and
628 controls. Significant association was observed between PAI-1
4G/5G gene polymorphism and CAD under an allelic genetic
model in the Chinese Han population (OR=1.70). This finding
suggested that the carriers with the 4 G allele of the PAI-1 4G/5G
gene in the Chinese Han population might be predisposed to
CAD.
In the subsequent meta-regression, the confounding factors
(publication year, study region, control size, total size, and RR)
could explain the heterogeneity. This result suggested that the
non-uniformity in the abovementioned factors contributed to the
heterogeneity among the individual studies. In a stratified analysis
by the total size, significantly increased risk was only detected in
subgroup 2 under an allelic genetic model. After adjusting for the
total sample size, unexplained heterogeneity still existed. The
association of PAI-1 4G/5G gene polymorphism with CAD was
evidently weakened in subgroup 1 and not yet significant
(OR=1.56). In contrast, the association of PAI-1 4G/5G gene
polymorphism with CAD was evidently strengthened in subgroup
2 (OR=2.03). Hence, further studies that can provide a match
between the sample sizes of cases and controls are warranted.
PAI-1 is a glycoprotein that belongs to the serine protease
inhibitor superfamily. It is equimolecularly combined with the
tissue plasminogen activator (tPA) single chain, double chains, and
double chain urokinase plasminogen activator (uPA). Consequent-
ly, tPA and uPA activities are rapidly inhibited by PAI-1. PAI-1 is
also an essential regulatory substance for in vivo plasminogen
activation. PAI-1, which is synthesized by endothelial cells and the
liver, is regulated by hormones and neurotransmitters. A dose-
response relationship has been found between PAI-1 and such
Table 4. The meta-regression results among 8 studies.
Coefficient Standard error T value P value 95% Confidence interval
RR 0.8320814 0.114808 7.25 0.019* 0.3381026,1.32606
Control size 0.0273875 0.0028546 9.59 0.011* 0.015105,0.03967
Region 21.174875 0.1413874 28.31 0.014* 21.783216,20.5665344
Publication year 0.1874112 0.0250733 7.47 0.017* 0.0795295,0.2952929
Total size 20.0120356 0.0012977 29.27 0.011* 20.0176192,-0.0064519
Cons 2374.732 50.28602 27.45 0.018* 2591.0953,2158.3687
Abbreviations: Control size: Control group sample size; Total size: Total sample size; RR: the ratio of case size to control size; Coefficient: regression coefficient;The
regression coefficients are the estimated increase in the lnOR per unit increase in the covariate as control size, RR, total size, region and publication year; cons:constant
item.
*P,0.05.
doi:10.1371/journal.pone.0033511.t004
Figure 2. Forest plot of coronary artery disease associated with 4G/5G gene polymorphism (distribution of 4G allelic frequency of
plasminogen activator inhibitor-1 4G/5G gene) stratified by total size.
doi:10.1371/journal.pone.0033511.g002
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demia, low high-density lipoprotein hyperlipidemia, hyperglyce-
mia, hyperinsulinemia, and physical labor deficiency [21].
PAI-1 4G/5G gene polymorphism is one of the DNA sequence
variations that plays a key role in regulating PAI-1 gene expression.
Studies have shown that the PAI-1 activity of the 4 G allele
promoter is higher than that of 5 G in a cytokine-stimulated state.
PAI-1 4G/5G gene polymorphism also influences PAI-1 gene
transcription similarly in non-stimulated cells [22]. The 4 G or
5 G allele could be combined with protein A, which is a
transcription activator. The 5 G allele could be incorporated with
protein B, which hinders the combination of the transcription
activator. The action locus is certified near the alleles. The 4 G
homozygote lacks the combination site with B factor, thus the 4 G
homozygote could not be combined with protein B, which
contributes to elevated plasma PAI-1 activity [23,24].
The relationship between PAI-1 4G/5G gene polymorphism
and CAD risk is subject to much controversy worldwide. In 2003,
Bo ¨ttiger C et al. reported that 4G/5G polymorphism of the PAI-1
gene is not associated with an increased risk of thrombotic and
restenotic events after coronary artery stenting in Germany [25].
In 2007, Sampaio MF et al. reported that acute myocardial
infarction (AMI) is not associated with PAI-1 gene polymorphisms
in young adults in Brazil [26]. By contrast, Juhan-Vague I et al.
found that PAI-1 played a role in MI risk in the presence of
underlying insulin resistance. A significant interaction between
insulin or proinsulin and –675 4G/5G polymorphism is observed
in MI risk in France [27]. In 2008, Onalan O et al. reported that
the PAI-1 4G/4G genotype is an independent predictor for the
development of MI in a Turkish population [28].
The present research has some limitations. Large-scale studies
on the relationship between PAI-1 4G/5G gene polymorphism
and CAD are still inadequate. PAI-1 is influenced not only by PAI-
1 4G/5G gene polymorphism, but also by environmental factors,
such as the concentration of blood sugar, insulin, triglycerides, and
so on [29]. Elevated plasma PAI-1 activity is also associated with
the progress of CAD. Plasma PAI-1 activity in the acute coronary
syndrome is much higher than that in stable CAD patients,
suggesting that PAI-1 plays a more important role in the acute
phase of CAD than in the other phases [30].
The current meta-analysis indicated that the 4 G allele of PAI-1
4G/5G gene polymorphism might increase the CAD risk in the
Chinese Han population. Therefore, significant potential guidance
for formulating CAD individual therapies is provided. Taking into
account the aforementioned limitations, further studies are highly
needed in the future.
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